Michael Dunn Reflects on all ASH25 Represents for the Bleeding Disorders Community
Michael Dunn, Vice President – Head of Rare Disease Portfolio at Genentech, shared on LinkedIn:
”I’m pausing to take a moment to reflect on all ASH25 represents for the bleeding disorders community – innovation, hope, progress.
I feel energized to be here.
Connecting with brilliant minds, learning about the latest advancements in hematology, and sharing how Genentech is advancing the standard of care for patients and their families.
I’m proud to be part of an organization that prioritizes standing alongside the hemophilia A community.
Every step forward is driven by our commitment to push the boundaries of what’s possible and deliver meaningful progress for people living with bleeding disorders.
A big thank you to the local Florida team for their above and beyond efforts at the booth Jeremy V., Lucila Ramirez Donaldson, William Lopez and to members of the leadership team who were representing our collective efforts for those with bleeding disorders Erik Lundgren, Tony Lin, Juliana Lagrasta Biondo, Gina Noh”
All from ASH25 featured in Hemostasis Today.
-
Jan 24, 2026, 15:54Nicolas Nesseler on How Common and Serious is Post-Op Bleeding After Heart Transplantation
-
Jan 24, 2026, 15:43Roey Tagansky on Tu Youyou and the Rediscovery That Defeated Malaria
-
Jan 24, 2026, 15:27Mavis Agnes Kisakye on Community Impact at HFU
-
Jan 24, 2026, 15:15Jo Jewell Announces Novartis Foundation and Novo Nordisk Collaboration
-
Jan 24, 2026, 15:02Todd Davenport on The Impacts of Long COVID
-
Jan 24, 2026, 14:47Seth D Ginsberg: Last Month, Something Meaningful Happened in Tokyo
-
Jan 24, 2026, 14:33Heghine Khachatryan on New Insights Into Bleeding Mechanisms in Acquired Hemophilia A
-
Jan 24, 2026, 14:21Mamta Soni Shares Highlights from CBC Chennai 2026
-
Jan 24, 2026, 13:52Larysa Mykhailova on Characterization of Allogeneic Platelet Gel